Creative Biomart Blog

Thu, 2023/03/30

The Base Editor Is Expected to Be Used for the Treatment of CD3Δ Severe Combined Immunodeficiency

In a new study, researchers from research institutions such as the University of California, Los Angeles, discovered that advanced genome editing technology may be able to be used for a rare and fatal genetic disease, D3 delta severe combined immunodeficiency, CD3δ SCID, for a one-time treatment. The relevant research results were published online in Cell, with the title “Human T cell generation is restored in CD3δ severe combined immunodeficiency through adenine base editing”. CD3δ SCID is caused by a mutation in the CD3D gene, which blocks the production of CD3δ proteins that are required

Thu, 2023/03/30

Understand the mechanism of action of CFTR to better treat cystic fibrosis

In a new study, researchers from St. Jude's Children's Research Hospital and Rockefeller University in the United States combined their expertise to gain a better understanding of a protein called cystic fibrosis transmembrane conductance regulator (CFTR). Mutations in CFTR cause cystic fibrosis, a fatal disease that cannot be cured. The relevant research results were published online in the journal Nature, with the title “CFTR function, physiology and pharmacology at single molecule resolution”. Currently, treatment with a drug called a potentiator can enhance the CFTR function of some pat

Thu, 2023/03/02

Interferon-gamma (IFNG) drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer

Immunotherapy - drug therapy that stimulates the immune system to attack tumors - has a good effect on some types of cancer, but its effect on lung cancer is mixed. A new study helps to clarify why the immune system responds so weakly to lung cancer, even after treatment with immunotherapy drugs. In this study on mice, researchers from the Massachusetts Institute of Technology found that bacteria found naturally in the lungs can help build an environment that inhibits the activation of T cells in lymph nodes near the lungs. They did not find that immunosuppressive environment in the lymph n

Thu, 2023/03/02

ROR2 may be a potential biomarker of prostate cancer

Prostate cancer (PCa) is the main cause of cancer-related deaths in men. Androgen deprivation therapy (ADT) is still the standard systemic treatment, but patients always progress to metastatic castrated tolerant prostate cancer (mCRP C). Most of these tumors will react to the further treatment of androgen signaling inhibitors (ASIs), but inevitably will produce drug resistance. Changes in androgen receptor (AR) and interaction pathway contribute to the sustained activity of AR and tumor growth in many cases, while other tumors are independent of AR, and some of them have neuroendocrine char

Thu, 2023/03/02

AMPK activation is a promising strategy to reduce the risk of melanoma

Skin cancer is the most common cancer in the United States, with about 5 million cases every year. Melanoma is less common than other types of skin cancer, including basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), but it causes most of the death of skin cancer. The risk of melanoma is related to environmental factors, such as ultraviolet radiation (UVR) and genetic background. It is noteworthy that the melanocortin-1 receptor (MC1R) is the central regulator of pigmentation and is related to the occurrence of melanoma. MC1R is a G-protein-coupled receptor, which plays a key rol

Thu, 2023/03/02

Autoimmunity in Down’s syndrome via cytokines

In a new study, researchers from the Icahn Medical College in Mount Sinai, the United States, determined which parts of the immune system of patients with Down's syndrome had problems, which led to autoimmune diseases. Relevant research results were published online in the journal Nature. This new study complements the findings of these authors published in the journal of Immunity in October 2022, that is, the frequency of viral infection in patients with Down's syndrome is lower, but more serious (Immunity, 2022, doi: 10.1016/j.immi.2022.09.007). By studying the laboratory samples of vo

Fri, 2023/02/17

The combination of PD1-IL2v and anti-PD-L1 can destroy the resistance of cancer to immunotherapy

Immunotherapy is a method of treating cancer by reprogramming the immune system of patients to attack their tumors. This cutting-edge treatment has had a significant impact on the treatment of cancer patients, and there have been cases of long-term remission. However, many patients either do not respond to immunotherapy, or even if they do, the effect is temporary, which highlights how important it is for us to better understand the mechanism that causes cancer to resist this treatment. In a new study, researchers from the Federal Institute of Technology in Lausanne, the University Hospi

Fri, 2023/02/17

The antiviral APOBEC3 protein actually promotes HIV to enter the latent state

In a new study, researchers described a discovery that violated the rules of the game in this field. Their research results show that a host protein family, which has long been considered as a pure antiviral substance, sometimes helps latent HIV find a safe harbor in patients. Understanding HIV latency at the molecular level is crucial for efforts to eliminate the virus scourge that causes immune deficiency syndrome (AIDS, commonly known as AIDS). Latent infection cell bank (also known as HIV virus bank) - HIV hides and persists in the body of infected patients in a silent standby mode - is